E Fund Management Co. Ltd. Sells 3,906 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

E Fund Management Co. Ltd. decreased its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 27.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,177 shares of the company’s stock after selling 3,906 shares during the period. E Fund Management Co. Ltd.’s holdings in Zentalis Pharmaceuticals were worth $42,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Eventide Asset Management LLC lifted its stake in shares of Zentalis Pharmaceuticals by 47.9% in the fourth quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock worth $175,134,000 after buying an additional 3,745,936 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Zentalis Pharmaceuticals by 20.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock worth $54,999,000 after acquiring an additional 585,644 shares during the last quarter. Decheng Capital LLC bought a new position in Zentalis Pharmaceuticals in the 4th quarter valued at approximately $31,809,000. Primecap Management Co. CA boosted its stake in Zentalis Pharmaceuticals by 5.8% during the 2nd quarter. Primecap Management Co. CA now owns 1,232,340 shares of the company’s stock valued at $5,040,000 after purchasing an additional 67,730 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Zentalis Pharmaceuticals by 152.6% during the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock valued at $2,706,000 after purchasing an additional 399,745 shares during the last quarter.

Zentalis Pharmaceuticals Trading Up 4.8 %

Shares of NASDAQ ZNTL opened at $4.36 on Friday. Zentalis Pharmaceuticals, Inc. has a 12-month low of $2.83 and a 12-month high of $23.12. The firm has a market capitalization of $310.04 million, a price-to-earnings ratio of -1.31 and a beta of 1.70. The firm has a 50 day moving average of $3.55 and a 200 day moving average of $8.51.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Friday, August 9th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.40). During the same quarter in the previous year, the company earned ($1.85) EPS. Sell-side analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.95 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ZNTL shares. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, August 12th. UBS Group downgraded shares of Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $28.00 to $5.00 in a report on Thursday, June 20th. Oppenheimer reissued an “outperform” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Monday. Stifel Nicolaus lowered their price objective on shares of Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, June 18th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $6.00 target price (down previously from $42.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday, June 18th. Seven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $10.78.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.